Treats relapsing forms of multiple sclerosis (MS). ANDA 210377, held by Macleods Pharmaceuticals. Dimethyl Fumarate.
As of Nov 21, 2026, ANDA 210377 (Dimethyl Fumarate), held by Macleods Pharmaceuticals, was first approved by FDA on Jun 26, 2024, with 0 approved supplements and 0 published complete response letters.
Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 26, 2024 | Original application | Approved | None posted |
| Dimethyl Fumarate120MG · capsule, delayed release;oral | Dimethyl Fumarate | Rx |
| Dimethyl Fumarate240MG · capsule, delayed release;oral | Dimethyl Fumarate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters